Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Growth Metrics

Pharma-Bio Serv (PBSV) Cash from Discontinued Operations (2018)

Pharma-Bio Serv filings provide 1 years of Cash from Discontinued Operations readings, the most recent being 2325159.0 for Q4 2018.

On a quarterly basis, Cash from Discontinued Operations changed N/A to 2325159.0 in Q4 2018 year-over-year; TTM through Jul 2019 was 2325159.0, a N/A change, with the full-year FY2018 number at 2728726.0, up 447.3% from a year prior.
Cash from Discontinued Operations hit 2325159.0 in Q4 2018 for Pharma-Bio Serv, up from 559219.0 in the prior quarter.
In the past five years, Cash from Discontinued Operations ranged from a high of 2325159.0 in Q4 2018 to a low of 277995.0 in Q2 2018.